IRIDEX

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRIDEX reports Q1 revenue decline, explores strategic growth opportunities

IRIDEX faces challenges with longer sales cycles and margin pressure but maintains leadership in its core business areas.
Strategic discussions for potential transactions offer growth opportunities for the company and its stockholders.
Addressing revenue decline in retina products and improving cash position are key focus areas for future performance.

IRIDEX reports Q3 mixed results, focuses on cost-cutting and growth

IRIDEX reported mixed financial performance in Q3 2024 with a decline in total revenue but growth in Cyclo G6 product sales.
Efforts to address cash burn through cost-cutting measures and strategic review progress were highlighted.
Challenges in the retina business were noted, but opportunities for improvement in glaucoma products and cost efficiencies were emphasized.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Iridex (IRIX) Q1 Earnings Expected to Decline

Iridex's (IRIX) fourth-quarter 2020 results benefit from strong product line-up and expanding market position.

Iridex (IRIX) Beats on Q4 Earnings, Revenues Increase Y/Y

Iridex Corporation (IRIX) CEO David Bruce on Q4 2020 Results - Earnings Call Transcript

Shares of Iridex (NASDAQ:IRIX) decreased 0.4% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 90.91% year over year to ($0.01), which beat the estimate of ($0.10).

Iridex: Q4 Earnings Insights

MOUNTAIN VIEW, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2021.

Iridex Announces Fourth Quarter and Full Year 2020 Financial Results

Iridex (NASDAQ:IRIX) releases its next round of earnings this Monday, March 22. Here is Benzinga's essential guide to Iridex's Q4 earnings report.

Preview: Iridex's Earnings

Iridex (IRIX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MOUNTAIN VIEW, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed the previously announced transaction with Topcon Corporation. Under the terms of the agreements, Topcon Corporation and its affiliates have completed the $10 million equity investment in Iridex and the purchase of exclusive distribution rights to the Iridex products in Asia Pacific and key EMEA regions, and Iridex has completed the purchase of assets related to PASCAL® laser products. The total transaction results in a net amount of $19.5 million to Iridex. The transaction was announced on March 2, 2021.

Iridex Completes Transaction with Topcon Corporation

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year of 2020 after the close of trading on Monday, March 22, 2021. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Iridex to Report Fourth Quarter and Full Year 2020 Financial Results on March 22, 2021

Iridex (IRIX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

The stock price of IRIDEX Corporation (NASDAQ: IRIX) is trading at over 20% pre-market. This is why it happened.

IRIX Stock Price Increases Over 20% Pre-Market: Why It Happened

MOUNTAIN VIEW, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has entered into a strategic collaboration with Topcon Corporation. Topcon is a Japanese-based manufacturer and distributor with approximately $1.3 billion in annual revenues, including $430 million from its eye care business.

Iridex Announces Strategic Collaboration with Topcon Corporation

MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 2, 2021.

IRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2020

Iridex Corp. seems to be at the initial stage of a growth inflection that could drive the stock up 175-625%. IRIX has a commercial product which could revolutionize glaucoma treatment, with an addressable market of $1.2 bil+.

Iridex To Benefit From New Revolutionary Glaucoma Treatment

MOUNTAIN VIEW, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, reports that MicroPulse Transscleral Laser Therapy (TLT), which is performed using the IRIDEX Cyclo G6® Laser System and MicroPulse P3® Delivery Device, has been included in the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma. The EGS guidelines represent recommendations on the diagnosis and management of glaucoma to standardize practice within the European Union. The new guidelines, the Society's 5th edition, were presented at the Annual EGS Meeting on December 12-13, 2020.

IRIDEX Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelines

IRIDEX's (IRIX) CEO Dave Bruce on Q3 2020 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020.

IRIDEX Announces Third Quarter 2020 Financial Results

Iridex (NASDAQ: IRIX) unveils its next round of earnings this Monday, November 09. Get prepared with Benzinga's ultimate preview for Iridex's Q3 earnings.

Earnings Outlook For Iridex

MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Virtual Healthcare Conference.

IRIDEX to Present at the 2020 Stifel Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the close of trading on Monday, November 9, 2020. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

IRIDEX to Report Third Quarter 2020 Financial Results on November 9, 2020

IRIDEX's (IRIX) CEO Dave Bruce on Q2 2020 Results - Earnings Call Transcript

Iridex Corporation: Deserves More Patience Given Shift In Commercial Strategy And Aggressive Cost Cutting

MOUNTAIN VIEW, Calif., Aug.  06, 2020  (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 27, 2020.

IRIDEX Announces Second Quarter 2020 Financial Results

Analysts Estimate Iridex (IRIX) to Report a Decline in Earnings: What to Look Out for

MOUNTAIN VIEW, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2020 after the close of trading on Thursday, August 6, 2020.  The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

News for IRIDEX Stock (IRIX)